140 related articles for article (PubMed ID: 25555732)
1. Discovery of triazolone derivatives as novel, potent stearoyl-CoA desaturase-1 (SCD1) inhibitors.
Sun S; Zhang Z; Pokrovskaia N; Chowdhury S; Jia Q; Chang E; Khakh K; Kwan R; McLaren DG; Radomski CC; Ratkay LG; Fu J; Dales NA; Winther MD
Bioorg Med Chem; 2015 Feb; 23(3):455-65. PubMed ID: 25555732
[TBL] [Abstract][Full Text] [Related]
2. Discovery of thiazolylpyridinone SCD1 inhibitors with preferential liver distribution and reduced mechanism-based adverse effects.
Sun S; Zhang Z; Raina V; Pokrovskaia N; Hou D; Namdari R; Khakh K; Ratkay LG; McLaren DG; Mork M; Fu J; Ferreira S; Hubbard B; Winther MD; Dales N
Bioorg Med Chem Lett; 2014 Jan; 24(2):526-31. PubMed ID: 24370012
[TBL] [Abstract][Full Text] [Related]
3. Systematic evaluation of amide bioisosteres leading to the discovery of novel and potent thiazolylimidazolidinone inhibitors of SCD1 for the treatment of metabolic diseases.
Sun S; Zhang Z; Kodumuru V; Pokrovskaia N; Fonarev J; Jia Q; Leung PY; Tran J; Ratkay LG; McLaren DG; Radomski C; Chowdhury S; Fu J; Hubbard B; Winther MD; Dales NA
Bioorg Med Chem Lett; 2014 Jan; 24(2):520-5. PubMed ID: 24374272
[TBL] [Abstract][Full Text] [Related]
4. Discovery and pharmacological characterization of SAR707 as novel and selective small molecule inhibitor of stearoyl-CoA desaturase (SCD1).
Voss MD; Zoller G; Matter H; Herling AW; Biemer-Daub G; Pfenninger A; Haag-Diergarten S; Keil S; Kohlmann M; Schmidts HL
Eur J Pharmacol; 2013 May; 707(1-3):140-6. PubMed ID: 23524088
[TBL] [Abstract][Full Text] [Related]
5. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable stearoyl-CoA desaturase-1 (SCD1) inhibitors: part 2. Pyridazine-based analogs.
Yang SM; Tang Y; Rano T; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Lang W; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2014 Mar; 24(5):1437-41. PubMed ID: 24405703
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in the discovery and development of stearoyl CoA desaturase inhibitors.
Uto Y
Chem Phys Lipids; 2016 May; 197():3-12. PubMed ID: 26344107
[TBL] [Abstract][Full Text] [Related]
7. Discovery of potent liver-selective stearoyl-CoA desaturase-1 (SCD1) inhibitors, thiazole-4-acetic acid derivatives, for the treatment of diabetes, hepatic steatosis, and obesity.
Iida T; Ubukata M; Mitani I; Nakagawa Y; Maeda K; Imai H; Ogoshi Y; Hotta T; Sakata S; Sano R; Morinaga H; Negoro T; Oshida S; Tanaka M; Inaba T
Eur J Med Chem; 2018 Oct; 158():832-852. PubMed ID: 30248655
[TBL] [Abstract][Full Text] [Related]
8. 4-Bicyclic heteroaryl-piperidine derivatives as potent, orally bioavailable Stearoyl-CoA desaturase-1 (SCD1) inhibitors. Part 1: urea-based analogs.
Yang SM; Tang Y; Zhang R; Lu H; Kuo GH; Gaul MD; Li Y; Ho G; Conway JG; Liang Y; Lenhard JM; Demarest KT; Murray WV
Bioorg Med Chem Lett; 2013 Dec; 23(24):6773-6. PubMed ID: 24153205
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in stearoyl-CoA desaturase 1 inhibitors for dyslipidemia and obesity.
Liu G
Curr Top Med Chem; 2010; 10(4):419-33. PubMed ID: 20180759
[TBL] [Abstract][Full Text] [Related]
10. Opportunities and challenges in developing stearoyl-coenzyme A desaturase-1 inhibitors as novel therapeutics for human disease.
Zhang Z; Dales NA; Winther MD
J Med Chem; 2014 Jun; 57(12):5039-56. PubMed ID: 24295027
[TBL] [Abstract][Full Text] [Related]
11. Development of a high-throughput screening assay for stearoyl-CoA desaturase using rat liver microsomes, deuterium labeled stearoyl-CoA and mass spectrometry.
Soulard P; McLaughlin M; Stevens J; Connolly B; Coli R; Wang L; Moore J; Kuo MS; LaMarr WA; Ozbal CC; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):105-11. PubMed ID: 18790133
[TBL] [Abstract][Full Text] [Related]
12. Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors.
Xin Z; Zhao H; Serby MD; Liu B; Liu M; Szczepankiewicz BG; Nelson LT; Smith HT; Suhar TS; Janis RS; Cao N; Camp HS; Collins CA; Sham HL; Surowy TK; Liu G
Bioorg Med Chem Lett; 2008 Aug; 18(15):4298-302. PubMed ID: 18632269
[TBL] [Abstract][Full Text] [Related]
13. Benzimidazole-carboxamides as potent and bioavailable stearoyl-CoA desaturase (SCD1) inhibitors from ligand-based virtual screening and chemical optimization.
Matter H; Zoller G; Herling AW; Sanchez-Arias JA; Philippo C; Namane C; Kohlmann M; Pfenninger A; Voss MD
Bioorg Med Chem Lett; 2013 Mar; 23(6):1817-22. PubMed ID: 23395660
[TBL] [Abstract][Full Text] [Related]
14. Discovery of potent and liver-targeted stearoyl-CoA desaturase (SCD) inhibitors in a bispyrrolidine series.
Lachance N; Gareau Y; Guiral S; Huang Z; Isabel E; Leclerc JP; Léger S; Martins E; Nadeau C; Oballa RM; Ouellet SG; Powell DA; Ramtohul YK; Tranmer GK; Trinh T; Wang H; Zhang L
Bioorg Med Chem Lett; 2012 Jan; 22(2):980-4. PubMed ID: 22209206
[TBL] [Abstract][Full Text] [Related]
15. Discovery of Novel and Potent Stearoyl Coenzyme A Desaturase 1 (SCD1) Inhibitors as Anticancer Agents.
Imamura K; Tomita N; Kawakita Y; Ito Y; Ono K; Nii N; Miyazaki T; Yonemori K; Tawada M; Sumi H; Satoh Y; Yamamoto Y; Miyahisa I; Sasaki M; Satomi Y; Hirayama M; Nishigaki R; Maezaki H
Bioorg Med Chem; 2017 Jul; 25(14):3768-3779. PubMed ID: 28571972
[TBL] [Abstract][Full Text] [Related]
16. Novel substituted heteroaromatic compounds as inhibitors of stearoyl-CoA desaturase.
Dobrzyn P; Dobrzyn A
Expert Opin Ther Pat; 2010 Jun; 20(6):849-53. PubMed ID: 20205608
[TBL] [Abstract][Full Text] [Related]
17. Development of a novel LC/MS method to quantitate cellular stearoyl-CoA desaturase activity.
Dillon R; Greig MJ; Bhat BG
Anal Chim Acta; 2008 Oct; 627(1):99-104. PubMed ID: 18790132
[TBL] [Abstract][Full Text] [Related]
18. Bicyclic heteroaryl inhibitors of stearoyl-CoA desaturase: from systemic to liver-targeting inhibitors.
Ramtohul YK; Powell D; Leclerc JP; Leger S; Oballa R; Black C; Isabel E; Li CS; Crane S; Robichaud J; Guay J; Guiral S; Zhang L; Huang Z
Bioorg Med Chem Lett; 2011 Oct; 21(19):5692-6. PubMed ID: 21871798
[TBL] [Abstract][Full Text] [Related]
19. Discovery of piperazin-1-ylpyridazine-based potent and selective stearoyl-CoA desaturase-1 inhibitors for the treatment of obesity and metabolic syndrome.
Zhang Z; Sun S; Kodumuru V; Hou D; Liu S; Chakka N; Sviridov S; Chowdhury S; McLaren DG; Ratkay LG; Khakh K; Cheng X; Gschwend HW; Kamboj R; Fu J; Winther MD
J Med Chem; 2013 Jan; 56(2):568-83. PubMed ID: 23245208
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological inhibition of stearoyl-CoA desaturase 1 improves insulin sensitivity in insulin-resistant rat models.
Issandou M; Bouillot A; Brusq JM; Forest MC; Grillot D; Guillard R; Martin S; Michiels C; Sulpice T; Daugan A
Eur J Pharmacol; 2009 Sep; 618(1-3):28-36. PubMed ID: 19616540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
